INFI - Infinity slips 8% on capital raise

Infinity Pharmaceuticals (INFI) down 8% premarket after pricing its public offering of 21M common shares at $3.80/share.Expected gross proceeds are $79.8M.Underwriters' over-allotment is an additional 3.15M shares. Net proceeds will be used for the development of eganelisib, for general corporate purposes and for working capital.Closing date is February 17.INFI has rallied around 21% over the past week on the heels of eganelisib study in urothelial cancer.Infinity Pharmaceuticals rises ~10% on upgrade indicating 'interesting opportunity' on lead assetPreviously (Feb. 11): Infinity Pharmaceuticals readies stock offering

For further details see:

Infinity slips 8% on capital raise